Mirum Pharmaceuticals, Inc. (MIRM)

Market Cap	5.74B +153.2%
Revenue (ttm)	521.31M +54.7%
Net Income	-23.36M
EPS	-0.47
Shares Out	60.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	722,852
Open	98.95
Previous Close	98.95
Day's Range	92.77 - 99.23
52-Week Range	37.33 - 109.28
Beta	0.52
Analysts	Strong Buy
Price Target	115.33 (+21.15%)
Earnings Date	May 6, 2026

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 372
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRM
• Website: https://www.mirumpharma.com

Financial Performance

In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $115.33, which is an increase of 21.15% from the latest price.

Price Target

$115.33

(21.15% upside)

Analyst Consensus: Strong Buy